晚期皮肤T细胞淋巴瘤:蕈样肉芽肿与Sézary综合征的治疗综述
该综述聚焦晚期蕈样肉芽肿与Sézary综合征(MF/SS)的治疗挑战,涵盖诊断延迟、生活质量影响、多线治疗需求、多学科协作及累积药物毒性限制用药时长,并汇总CTCL生物学进展如何转化为晚期及复发疾病的治疗选择。
要点
- MF/SS为不可治愈但可治疗疾病,需多学科协作及早期转诊至CTCL中心。
- 诊断延迟、生活质量损害与累积药物毒性是影响治疗持续性的关键挑战。
- CTCL生物学进展正被用于拓展晚期及复发疾病的治疗选择。
核心结论
- MF/SS属不可治愈但可治疗疾病,其管理面临诊断延迟、生活质量损害、多线治疗需求、多学科协作及累积药物毒性限制用药时长等多重挑战。
研究设计与样本
- 本文为综述,旨在概述CTCL生物学最新进展及其向晚期和复发疾病治疗选择的转化,并总结不同治疗模式以强调多学科协作和早期转诊至CTCL中心的重要性。
主要发现
- CTCL的生物学进展正被用于为晚期和复发疾病提供额外治疗选择。
临床怎么用
- 晚期MF/SS管理应重视多学科协作,并早期转诊至CTCL中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell lymphomas (TCLs) constitute a rare subset of non-Hodgkin lymphomas, with mycosis fungoides/Sézary syndrome (MF/SS) being the most common subtype of cutaneous TCLs (CTCLs). Considered an incurable but treatable disease, MF/SS management presents several challenges including diagnostic delays, debilitating effect on patients' quality of life, need for several lines of therapies, multidisciplinary care and cumulative drug toxicities limiting duration of use. The present review intends to provide an overview of the recent advances in our understanding of the biology of CTCL and how these are being leveraged to provide additional treatment options for management of advanced and recurrent disease. In addition, the discussion of the different modalities of treatment is summarised to further outline the importance of multidisciplinary care and early referral to CTCL centres.
引用
- Sethi TK, Montanari F, Foss F, et al. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome. Br J Haematol. 2021. PMID: 33987825. doi:10.1111/bjh.17458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。